1980
DOI: 10.1128/aac.18.6.913
|View full text |Cite
|
Sign up to set email alerts
|

Ro 13-9904, a long-acting broad-spectrum cephalosporin: in vitro and in vivo studies

Abstract: Ro 13-9904, a new parenteral cephalosporin, was found to have high in vitro activity against Enterobacteriaceae and other gram-negative bacteria, including various isolates resistant to cefuroxime, cefamandole, cefoxitin, and cefazolin. It showed promising activity against Pseudomonas aeruginosa. Although inhibitory against Staphylococcus aureus at concentrations readily achievable in plasma, it was less potent against this pathogen than cefamandole, cefazolin, or cefuroxime.Isolates of Streptococcus faecalis … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

3
43
0
2

Year Published

1983
1983
2010
2010

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 88 publications
(48 citation statements)
references
References 23 publications
3
43
0
2
Order By: Relevance
“…Here, the 3-lactam treatments administered at usual doses (20 mg/kg) (2,4,26,27,29) demonstrated less efficacy than classic treatments such as gentamicin or doxycycline. Therefore, a treatment can be considered really successful when administration of the drug leads to a decrease in the growth kinetics curves and not merely to a significant difference between treated and nontreated groups of mice.…”
Section: Resultsmentioning
confidence: 99%
“…Here, the 3-lactam treatments administered at usual doses (20 mg/kg) (2,4,26,27,29) demonstrated less efficacy than classic treatments such as gentamicin or doxycycline. Therefore, a treatment can be considered really successful when administration of the drug leads to a decrease in the growth kinetics curves and not merely to a significant difference between treated and nontreated groups of mice.…”
Section: Resultsmentioning
confidence: 99%
“…Ceftriaxone is a broad spectrum antibiotic that displays potent activity against gram-positive and gram-negative bacteria (Angehrn et al, 1980). The pharmacokinteic parameters of ceftriaxone and sulbactam alone has been reported in several literatures (Foulds et al, 1983;Patel et al, 1981;Meyers et al, 1983).…”
Section: Discussionmentioning
confidence: 99%
“…Microbiol., in press); and (ii) altered platelet aggregation and bleeding disturbances at the maximal dosages necessary for the therapy of central nervous system infections (29). The in vitro activities of ceftriaxone and cefotaxime are nearly identical (1,14,17,28,39;Scheld et al, in press), including the activities against the major meningeal pathogens, and both of these agents have proven efficacy in the therapy of meningitis in humans (2,6,8,12,29,40). The clinical experience with ceftriaxone exceeds that with cefotaxime alone for this disease.…”
mentioning
confidence: 99%
“…Ceftriaxone (RO13-9904) is a new third-generation cephalosporin with excellent in vitro activity against all major meningeal pathogens (1,14,17,28,39; Scheld, Rocha, Sande, and Bryan, Am. J.…”
mentioning
confidence: 99%